AtheroGenics Enrolls First Patients in ANDES Trial

AtheroGenics has commenced enrollment in the ANDES trial to evaluate AGI-1067 for diabetes.

ANDES is a double-blind, placebo-controlled study being conducted at sites in the U.S., South Africa, Eastern Europe and India. The trial is designed to randomly assign approximately 1,200 patients with Type II diabetes mellitus to 75-, 150- and 300-mg dose levels of AGI-1067 or placebo for 25 weeks, ArtheroGenics said.

According to the company, all patients will be on either one or no antidiabetic medication. The key objective of ANDES is to compare the effects three doses of AGI-1067 versus placebo on glycemic endpoints.

The company said it expects to conclude the study before the end of 2008.